STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB): For the first time, a clinical phase III program has demonstrated that it is possible to prevent cold sores by early treatment initiation. The entire phase III program comprised almost 3000 patients in five studies, the pivotal trial being the largest ever conducted with 1443 patients treated out of 2437 recruited. Treatment with Lipsovir® prevented the development of cold sores in 42% of patients. In those patients who nevertheless developed a cold sore, the healing time and severity were significantly reduced.
